Skip to content

Author

Jun Cao

We have 2 of 10 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Trastuzumab-TKI combination in HER2-Positive tumors: a FAERS-Based safety profile and multimodal analysis of Tanespimycin’s role in enhancing targeting of the HSP90AA1-PI3K-Akt-mTOR axis

Background This study addresses the safety profiles and molecular mechanisms of trastuzumab monotherapy and its combination with lapatinib, neratinib, and tucatinib for treating HER2-positive tumors. Methods The research integrates a multi-platform approach, including data from the US Food and Drug Administration Adver...

Xiao Chen, Xiao Han, Yuan-Yuan Zhang et al. · 0 citations
Open access Aug 2026

A programmed cell death learning signature predicts immunotherapy response and identifies AP1S1 as a regulator of immune exclusion in breast cancer.

This study establishes the PCDsig developed is a potential prognostic and predictive biomarker for breast cancer and provides the first evidence of AP1S1 as a core immunomodulatory oncogene that mediates immune exclusion.

Gui-Xin Wang, Jun Cao, Parhat Kaysar et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.